-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Rituximab and Eculizumab when Treating Non-Malignant Hematologic Disorders: Infection Risk, Immunization Recommendations, Antimicrobial Prophylaxis Needs

Program: Education Program
Session: Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis Needs when Treating Non-Malignant Hematologic Disorders - Wash Your Hands and What Else?
Monday, December 7, 2020, 6:55 AM-7:00 AM

Jolan E. Walter, MD, PhD

Department of Medicine, Johns Hopkins All Children's Hospital, St Petersburg, FL; Department of Medicine, Johns Hopkins All Children Hospital, St Petersburg, FL; Massachusetts General Hospital for Children, Boston, MA

Disclosures: Walter: Lediant: Research Funding; Octapharma: Research Funding; X4 Pharmaceuticals: Consultancy, Research Funding; Takeda: Research Funding, Speakers Bureau.

See more of: Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis Needs when Treating Non-Malignant Hematologic Disorders - Wash Your Hands and What Else?
See more of: Education Program
<< Previous Presentation | Next Presentation